Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

OKI-219

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

OnKure

Drug class:

PI3Kα H1047R mutation inhibitor

Related drugs:

‹

›

PIK3CA H1047R	Breast Cancer	PIK3CA H1047R	Breast Cancer	OKI-219 Sensitive: D – Preclinical OKI-219 Sensitive : D	OKI-219 Sensitive: D – Preclinical OKI-219 Sensitive : D
ER positive + PIK3CA H1047R	Breast Cancer	ER positive + PIK3CA H1047R	Breast Cancer	AZD9833 + OKI-219 Sensitive: D – Preclinical AZD9833 + OKI-219 Sensitive : D	AZD9833 + OKI-219 Sensitive: D – Preclinical AZD9833 + OKI-219 Sensitive : D
ER positive + PIK3CA H1047R	Breast Cancer	ER positive + PIK3CA H1047R	Breast Cancer	elacestrant + OKI-219 Sensitive: D – Preclinical elacestrant + OKI-219 Sensitive : D	elacestrant + OKI-219 Sensitive: D – Preclinical elacestrant + OKI-219 Sensitive : D
ER positive + PIK3CA H1047R	Breast Cancer	ER positive + PIK3CA H1047R	Breast Cancer	OKI-219 Sensitive: D – Preclinical OKI-219 Sensitive : D	OKI-219 Sensitive: D – Preclinical OKI-219 Sensitive : D
ER negative + PIK3CA H1047R	Breast Cancer	ER negative + PIK3CA H1047R	Breast Cancer	tucatinib + OKI-219 Sensitive: D – Preclinical tucatinib + OKI-219 Sensitive : D	tucatinib + OKI-219 Sensitive: D – Preclinical tucatinib + OKI-219 Sensitive : D